AI gets access to big novel chemistry space for quick and effective drug discovery
San Diego (CA) - Insilico
Medicine, in collaboration with ChemDiv, Inc., launched a drug discoveryinitiative that aims to use the power of artificial intelligence for screeningchemistry space with newly designed compounds. Theinitiative is expected to identify a massive of drug candidates in early stages. That became possible because AI canscan a vast number of compounds at higher speeds and with improved accuracycompared to traditional screening projects. The newproject is aimed at rapidly screening targets in various therapeutic areas,including oncology, metabolism, immunology, urology and others.“We have
successfully identified early drug candidates by screening a limited number ofcompounds with our AI virtual screening platform,” said Alex Zhavoronkov,Ph.D., Founder and CEO of Insilico Medicine. “ChemDiv significantly increasesour capabilities by opening a great lead-like and drug-like novel chemicalspace with reliable support. Our joint effort to evaluate these diversecompounds increases the likelihood of developing new drugs for existing targetswith less adverse effects.”“We are connecting AI technology with ChemDiv's efforts and investments in the design and validation of novel chemistry,” said Sergey Bugrov, Executive Director, ChemDiv. “The feasible chemical space of 3 billion molecules partitioned in validated unique scaffolds and available for modeling is represented by 1.7 million physical compounds. This new approach, will immediately provide researchers with many more starting points for drug discovery and significantly improve their process”.
About ChemDiv
ChemDiv is a recognized global leader in drug discovery
solutions. Over the past 29 years ChemDiv has delivered hundreds of leads, drugcandidates and new drugs in the area of CNS, oncology, virology, inflammation,cardiometabolic and immunology, to pharma, biotech and academic partners aroundthe globe. [www.chemdiv.com]About Insilico Medicine
Insilico
Medicine is an artificial intelligence company headquartered in Hong Kong, withoffices in six countries and regions. The Company was the first to apply thegenerative adversarial networks (GANs) and reinforcement learning (RL) togenerate new molecular structures with the specified parameters in 2015. Inaddition to collaborating with large pharmaceutical companies, InsilicoMedicine is also pursuing internal drug discovery programs in different diseaseareas and anti-aging fields. Recently, Insilico Medicine published some of theresuts in Nature Biotechnology, andsecured $37 million in series B funding. Website http://insilico.com/Media Contacts
For further information, images or interviews, please contact:
Insilico Medicine: Klug Gehilfe, ai@insilico.com
ChemDiv Inc.: Ron Demuth, rd@chemdiv.com